The Supreme Court recently decided two cases in which the central question was whether certain patent claims involving natural materials and biomolecules constituted patent eligible subject matter under 35 U.S.C. §101. In Mayo Collaborative Services v. Prometheus Laboratories,1 the U.S. Supreme Court held that patent claims to "relationships between concentrations of certain metabolites in the blood and the likelihood that a dosage ... will prove ineffective or cause harm" are not patent eligible because they generally recite a law of nature, and the addition of certain claim steps directed to "well understood, routine, conventional activity" does not change that conclusion. In Association for Molecular Pathology v. Myriad Genetics,2 the court held that "genes and the information they encode are not patent eligible under §101 simply because they have been isolated from the surrounding genetic material."
Click here to continue reading the full text and footnotes of this article
Originally published in the April 13, 2015 edition of the New York Law Journal
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
